Description
The Germline 3 Gene Panel is a comprehensive hereditary cancer genetic test that evaluates three high-impact cancer susceptibility genes: BRCA1 gene, BRCA2 gene, and TP53 gene.
Mutations in BRCA1/BRCA2 are strongly associated with Hereditary Breast and Ovarian Cancer (HBOC), while TP53 mutations are linked to Li-Fraumeni syndrome—a rare but severe condition that significantly increases the risk of early-onset cancers, including sarcomas, breast cancer, brain tumors, and leukemia.
This NGS-based genetic panel test plays a crucial role in precision oncology, early cancer detection, and personalized treatment planning. Non-fasting.
Sample Required:
The Germline 3 Gene Panel requires a blood sample, collected in an EDTA vacutainer (purple top). The sample must be maintained under refrigerated conditions (2–8°C) and transported within 72 hours.
Test Time:
The test results are typically available within 10–14 days, depending on sequencing and analysis workflows.
Test Normal Range:
The normal result is no pathogenic or likely pathogenic mutation detected in BRCA1, BRCA2, or TP53 genes.
- Negative: No clinically significant mutation identified
- Positive: Pathogenic mutation detected (increased cancer risk)
- VUS (Variant of Uncertain Significance): Requires further evaluation and genetic counseling
What is the test?
The Germline 3 Gene Panel is an advanced Next-Generation Sequencing (NGS) test designed for hereditary cancer screening. It identifies inherited mutations in BRCA1, BRCA2, and TP53 genes that are associated with high lifetime cancer risk.
This test is widely used in:
- Cancer risk assessment programs
- Precision medicine and targeted therapy planning
- Genetic counseling and family screening
Test Procedure:
A blood sample is collected and processed using high-depth NGS sequencing (~450x coverage). The DNA is analyzed for mutations, deletions, and duplications in the selected genes. Results are interpreted by molecular genetic specialists and oncologists.
When to take the test?
This test is recommended in the following situations:
- Early-onset breast cancer (especially <40 years)
- Individuals with multiple primary cancers
- Family history of BRCA-related cancers or Li-Fraumeni syndrome
- History of childhood cancers such as sarcoma or brain tumors
- Prior to treatment planning (chemotherapy/radiation sensitivity)
- For clinical trial eligibility and targeted therapies
Who should take this test?
- Patients with strong hereditary cancer history
- Individuals with triple-negative breast cancer
- Families with rare or early-onset cancers
- Patients suspected of Li-Fraumeni syndrome
- Individuals seeking comprehensive genetic cancer screening
- People planning preventive oncology strategies and family risk assessment
Precautions for exceptional cases (pregnancy etc.):
Pregnant individuals or those with complex medical conditions should consult their healthcare provider before testing. Genetic counseling is highly recommended before and after testing to understand the implications for both the individual and their family members.
Genes Covered
- BRCA1
- BRCA2
- TP53
Indications for Testing
- Early-onset breast cancer or multiple cancers in one individual
- Family history of BRCA1/BRCA2 or TP53-associated cancers
- Suspected Li-Fraumeni syndrome (LFS)
- History of sarcoma, brain tumors, or childhood cancers
- To guide chemotherapy response and radiation therapy decisions
Inheritance Pattern
Pathogenic mutations in BRCA1, BRCA2, and TP53 follow an autosomal dominant inheritance pattern:
- A single mutated copy increases cancer risk
- 50% chance of transmission to first-degree relatives
- Supports family-wide genetic screening and preventive care
Why is This Test Important?
The Germline 3 Gene Panel enables:
- Early identification of high-risk individuals
- Personalized cancer prevention and screening strategies
- Improved treatment decision-making (precision oncology)
- Identification of Li-Fraumeni syndrome and HBOC
- Better long-term survival outcomes through proactive care
Applicable Cancers
- Breast Cancer
- Ovarian Cancer
- Fallopian Tube Cancer
- Prostate Cancer
- Pancreatic Cancer
- Uterine & Cervical Cancer
- Testicular Cancer
- Skin Cancer
- Brain Tumors
- Hematologic Malignancies
- Liver Cancer
- Soft Tissue Sarcoma
- Adrenal Cancer
Technical Information
- Methodology: Next-Generation Sequencing (NGS)
- Depth of Coverage: ~450x (high sensitivity and accuracy